August 12, 2014
Medical device manufacturers may need to re-think their approach to demonstrating substantial equivalence (SE) in the 510(k) notification process, due to the FDA’s recent finalization of the guidance document “The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications.” The release of the final version of this guidance cements certain changes to the core of the 510(k) program namely, FDA’s determination to disallow the use of ‘split predicates’ (using one predicate device for its intended use and another predicate device for technological characteristics), and its intention to require much more detail and specific information to be presented in the 510(k) Summary.
Although it is generally agreed that little has changed between the draft version (released December 27, 2011) and the final version, it should be noted that the final guidance document focuses only on the traditional 510(k). FDA announced that it will address and finalize the sections from the draft guidance on special and abbreviated 510(k)s in separate documents. The final guidance document also does not address combination products.
The new guidance includes non-binding recommendations that set out FDA’s current thinking on:
In addition, the guidance also offers updated information in its appendices:
The fact that this document contains very few changes from the draft is a reminder to medical device manufacturers to pay attention to the following major points:
FDA acknowledges that a new medical device does not need to be identical to its predicate in order to be designated as SE. The guidance document states that it is ‘rare’ for a new device to be identical to a device that is currently on the market. Companies must carefully navigate FDA’s requirements for demonstrating and documenting SE.
If you have any questions, please contact us.
December 8, 2016
In May 2014, the FDA published a guidance document entitled “Expedited Programs for Serious Conditions – Drugs and Biologics.” The intention of the document was to provide drug makers with an...
June 14, 2016
On Thursday, June 2nd the FDA issued a final guidance, entitled “Charging for Investigational Drugs Under an IND — Questions and Answers.” The guidance provides information concerning the...
June 8, 2022
Today, FDA published a new Manual of Policies and Procedures (MAPP), “Assessment of the User Interface of a Drug-Device Combination Product Submitted in a Pre-ANDA Communication or an ANDA (5223.6).”...